NEW HAVEN, Conn.--(BUSINESS WIRE)--Trevi Therapeutics, Inc. (“Trevi”), a late-stage clinical development company developing Nalbuphine ER for chronic pruritus conditions, will present two posters at the National Kidney Foundation Spring 2016 Meeting in Boston, MA on April 28.
The two posters regarding Trevi’s uremic pruritus clinical trials are Nalbuphine ER Tablets in Hemodialysis Patients with Severe Uremic Pruritus: Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial, and Long-Term Effects of Nalbuphine ER Tablets in Hemodialysis Patients with Uremic Pruritus: A Multicenter Open-Label Trial.
